KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Resmed's EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $2.68 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 14.53% year-over-year to $2.68; the TTM value through Dec 2025 reached $10.11, up 19.36%, while the annual FY2025 figure was $9.51, 37.43% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $2.68 in Q4 2025 per RMD's latest filing, up from $2.37 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.68 in Q4 2025 to a low of -$0.54 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.68, with a median of $1.54 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 148.21% in 2021, then skyrocketed 325.93% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.37 in 2021, then rose by 11.68% to $1.53 in 2022, then fell by 7.19% to $1.42 in 2023, then soared by 64.79% to $2.34 in 2024, then grew by 14.53% to $2.68 in 2025.
  • Per Business Quant, the three most recent readings for RMD's EPS (Weighted Average and Diluted) are $2.68 (Q4 2025), $2.37 (Q3 2025), and $2.58 (Q2 2025).